Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
Botulism01:22

Botulism

Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A prematurely terminated phase 2, randomised trial to evaluate immunogenicity and reactogenicity of a single versus two-dose primary vaccination regimen of the mRNA vaccine BNT162b2 in previously SARS-CoV-2 infected children 5-11 years old (CoVacc trial).

Vaccine·2026
Same author

Saying no to surgery for drooling: long-term drooling outcomes and developmental maturation after declining surgery.

Disability and rehabilitation·2026
Same author

From rigid to rapid: rethinking clinical trial processes for emergency-ready clinical trials.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same author

Validity, Reliability and Application of the Paediatric Posterior Drooling Scale.

Child: care, health and development·2025
Same author

Understanding posterior drooling in children and young people with neurodevelopmental disabilities: a parental perspective.

BMC pediatrics·2025
Same author

The ins and outs of glycopyrronium treatment for paediatric drooling: exploring the treatment journey using real-world data.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2025

Related Experiment Video

Updated: Jun 12, 2026

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
07:05

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

Botulinum toxin versus submandibular duct relocation for severe drooling.

Arthur R T Scheffer1, Corrie Erasmus, Karen VAN Hulst

  • 1Department of Otorhinolaryngology and Head and Neck Surgery, Radboud University Medical Centre, Nijmegen, the Netherlands. a.scheffer@kno.umcn.nl

Developmental Medicine and Child Neurology
|June 22, 2010
PubMed
Summary

Surgery significantly reduced drooling in children more effectively than Botulinum neurotoxin type A (BoNT-A) injections. Surgical re-routing of submandibular ducts offered a more substantial and enduring improvement for severe drooling management.

More Related Videos

Retroductal Submandibular Gland Instillation and Localized Fractionated Irradiation in a Rat Model of Salivary Hypofunction
07:44

Retroductal Submandibular Gland Instillation and Localized Fractionated Irradiation in a Rat Model of Salivary Hypofunction

Published on: April 24, 2016

Related Experiment Videos

Last Updated: Jun 12, 2026

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
07:05

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

Retroductal Submandibular Gland Instillation and Localized Fractionated Irradiation in a Rat Model of Salivary Hypofunction
07:44

Retroductal Submandibular Gland Instillation and Localized Fractionated Irradiation in a Rat Model of Salivary Hypofunction

Published on: April 24, 2016

Area of Science:

  • Pediatric Otolaryngology
  • Neurology
  • Surgical Interventions

Background:

  • Botulinum neurotoxin type A (BoNT-A) is increasingly used for drooling, but its efficacy relative to established treatments is unclear.
  • Severe drooling impacts quality of life in children with neurological conditions.

Purpose of the Study:

  • To compare the effectiveness of BoNT-A injections versus surgical re-routing of submandibular ducts for severe drooling in children and young adults.

Main Methods:

  • An observational study of 19 participants with severe drooling, comparing BoNT-A injections followed by surgery at least 6 months later.
  • The drooling quotient was measured before each intervention and at 8 and 32 weeks post-intervention.
  • Multivariate analysis of variance was used to analyze repeated measures.

Main Results:

  • Surgery resulted in a significantly greater reduction in the drooling quotient compared to BoNT-A (p=0.001).
  • Post-surgery, the mean drooling quotient decreased from 28 to 10 at 8 weeks and 4 at 32 weeks (p<0.001).
  • BoNT-A showed a significant reduction from 30 to 18 at 8 weeks (p=0.02), with diminished effect by 32 weeks (drooling quotient 22; p=0.05).

Conclusions:

  • Both BoNT-A and submandibular duct surgery are effective interventions for severe drooling.
  • Surgical intervention provides a more significant and longer-lasting reduction in drooling quotient compared to BoNT-A.